ERBB2 and triple-negative breast carcinoma: Systematic treatment of patients with nonmetastatic BC is determined by subtypes: hormone receptor-positive (HR+) patients receive endocrine therapy, and a few of them receive chemotherapy at the same time; human epidermal growth factor receptor 2-positive (HER2+) patients receive HER2-targeted antibody or small molecule inhibitor combined chemotherapy; due to the high heterogeneity, invasiveness, and lack of treatment options, chemotherapy is still the standard treatment for triple negative breast cancer (TNBC).